Abstract
Approximately 15% of patients with ulcerative colitis develop an acute attack of severe colitis, and 30% of these patients require colectomy. Severe ulcerative colitis is therefore considered a medical emergency, the management of which requires close collaboration between gastroenterologists and surgeons. The mortality rate for patients with severe ulcerative colitis is now <1% in specialist centers, but it was high before intravenous steroid therapy and early surgery were introduced; indeed, mortality is still high in nonspecialized centers. As colectomy severely affects quality of life, therapy with intravenous ciclosporin and, more recently, infliximab has been introduced to try to avoid the need for surgery. Ciclosporin induces short-term remission, but the long-term benefit remains unsatisfactory as colectomy is often only delayed. A significant short-term reduction in the colectomy rate has, however, been observed after infliximab treatment. The use of infliximab versus ciclosporin in patients with severe ulcerative colitis remains to be defined. The timing of surgery remains a cardinal decision in the management of severe ulcerative colitis; increased morbidity resulting from prolonged ineffective medical treatment and, therefore, a delay in surgical treatment should be avoided.
Key Points
-
An acute attack of severe ulcerative colitis must considered a medical emergency
-
The early detection of prognostic factors significantly reduces mortality in patients with severe ulcerative colitis
-
The finding of small-bowel distension on X-ray (so-called impending megacolon) identifies patients at high risk of developing toxic megacolon
-
Ciclosporin or infliximab can be used in patients with severe ulcerative colitis when there is no clear cut clinical response to an intensive treatment regimen with corticosteroids
-
A particularly aggressive therapeutic approach is appropriate in patients with symptoms of multiple organ dysfunction
-
The timing of colectomy remains the most important decision to be made by the gastroenterologist in conjunction with the surgeon
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sonnenberg A and Koch TR (1989) Period and generation effect on mortality from idiopathic inflammatory bowel disease. Dig Dis Sci 34: 1720–1729
Carter MJ et al. (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (Suppl V): V1–V16
Winther KV et al. (2003) Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125: 1576–1582
Card T et al. (2003) Mortality in Inflammatory Bowel Disease: a population-based cohort study. Gastroenterology 125: 1583–1590
Loftus EV Jr (2003) Mortality in inflammatory bowel disease: peril and promise. Gastroenterology 125: 1881–1883
Hardy TL and Bulmer E (1933) Ulcerative colitis: survey of 95 cases. Br Med J 2: 812–815
Rice-Oxley JM and Truelove SC (1950) Ulcerative colitis: course and prognosis. Lancet 1: 663–666
Truelove SC and Witts LJ (1955) Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 2: 1041–1048
Truelove SC and Jewell DP (1974) Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1: 1067–1070
Lichtiger S et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841–1845
D'Haens G et al. (2001) Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120: 1323–1329
Van Assche G et al. (2003) Randomized double-blind comparison of 4 mg/Kg versus 2 mg/Kg intravenous Cyclosporin in severe ulcerative colitis. Gastroenterology 125: 1025–1031
Campbell S et al. (2005) Cyclosporine use in acute ulcerative colitis: a long term experience. Eur J Gastroenterol Hepatol 17: 79–84
Probert CSJ et al. (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut 52: 998–1002
Rutgeerts P et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476
Jarnerot G et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805–1811
Shibolet O et al. (2005) Cyclosporine-A for induction of remission in severe ulcerative colitis. The Cochrane Database of Systematic Reviews Issue 1, Art. No CD004277
Silverberg MS et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease. Can J Gastroenterol 19 (Suppl A): 5–36
Jalan KN et al. (1969) An experience of ulcerative colitis. Gastroenterology 57: 68–82
Caprilli R et al. (2000) Multiple organ dysfunction in ulcerative colitis. Am J Gastroenterol 95: 1258–1262
Lennard-Jones JE et al. (1975) Assessment of severity in colitis: a preliminary study. Gut 16: 579–584
Caprilli R et al. (1976) Blood pH: a test for assessment of severity on proctocolitis. Gut 17: 763–769
Caprilli R et al. (1978) Salt loosing diarrhoea in idiopathic proctocolitis. Scand J Gastroenterol 13: 331–335
Caprilli R et al. (1980) Risk factors in toxic megacolon. Dig Dis Sci 25: 817–822
Travis SPL et al. (1996) Predicting outcome in severe ulcerative colitis. Gut 38: 905–910
Ahmad T et al. (2006) Genetics of inflammatory bowel disease: the role of HLA complex. World J Gastroenterol 12: 3628–3635
Ho GT et al. (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15: 797–805
Caprilli R et al. (1987) Early recognition of toxic megacolon. J Clin Gastroenterol 9: 160–164
Chew CN (1991) Small bowel gas in severe ulcerative colitis. Gut 32: 1535–1537
Caprilli R and Onori L (1992) Pathogenesis of gastrointestinal distension in severe ulcerative colitis: a hypothesis. Gastroenterol Int 5: 268–272
Jones JH and Chapman M (1969) Definition of megacolon in colitis. Gut 10: 562–564
Latella G et al. (2002) GI distension in severe ulcerative colitis. Am J Gastroenterol 97: 1169–1175
Mourelle M et al. (1995) Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology 109: 1497–1502
Onori L et al. (2005) Role of nitric oxide in the impairment of circular muscle contractility of distended, uninflamed mid-colon in TNBS-induced acute distal colitis in rats. World J Gastroenterol 11: 5677–5684
Carbonnel F et al. (1994) Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 39: 1550–1557
Carbonnel F et al. (2000) Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 14: 273–279
Buckell NA et al. (1980) Depth of ulceration in acute colitis. Correlation with outcome and clinical and radiological features. Gastroenterology 79: 19–25
Naber AHJ and de Jong DJ (2003) Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 61: 105–110
Seo M (1992) An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87: 971–976
Walmsley RS et al. (1998) A simple clinical colitis activity index. Gut 43: 29–32
Su C et al. (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97: 2577–2584
Lindgren SC (1998) Early predictors of glucocorticoid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10: 831–835
Higgins PDR et al. (2005) Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 100: 355–361
Truelove SC et al. (1978) Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 2: 1086–1088
Meyers S and Janowitz HD (1985) Corticosteroid therapy of ulcerative colitis. Gastroenterology 89: 1189–1191
Powell-Tuck J et al. (1977) A controlled trial of corticotrophin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 12: 971–975
Meyers S et al. (1983) Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 85: 351–357
Meyers S et al. (1987) Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 9: 50–54
Lees C et al. (2006) Infliximab is effective as rescue therapy for acute severe ulcerative colitis. The initial Edinburgh experience. Gastroenterology 130 (Suppl 2): A-656
Walsh A et al. (2006) Acute severe ulcerative colitis: a study of predictors of outcome and efficacy for Cyclosporin and Infliximab. Gastroenterology 130 (Suppl 2): A-84
Regueiro M et al. (2006) Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 40: 476–481
Lichtenstein GR et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621–630
Baumgart DC et al. (2005) The phase I/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with i.v. steroids. Gut 54 (Suppl VII): A57
Sawada K et al. (2005) Leukocytapheresis for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 10: 1–7
McIntyre DB et al. (1986) Controlled trial of bowel rest in the treatment of severe colitis. Gut 27: 481–485
Chapman RW et al. (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Gut 27: 1210–1212
Greenstein AJ et al. (1985) Outcome of toxic dilation in ulcerative colitis and Crohn's colitis. J Clin Gastroenterol 7: 137–143
Gan SI and Beck PL (2003) A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 98: 2363–2371
Imbriaco M et al. (2001) Toxic megacolon. Role of CT in evaluation and detection of complications. Clin Imaging 25: 349–354
Present DH et al. (1988) Medical decompression of toxic megacolon by “rolling”. J Clin Gastroenterol 10: 485–490
Panos MS et al. (1993) Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 34: 1726–1727
Buchman AL (2001) Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol 33: 337–339
Riedel L (1989) Endoscopic decompression in toxic megacolon. Surg Endosc 3: 51
Cottone M et al. (2001) Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 96: 773–775
Kambham N et al. (2004) Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 28: 365–373
Zer M et al. (1972) Pitfalls in the surgical management of fulminating ulcerative colitis. Dis Colon Rectum 15: 280–287
Softley A et al. (1988) Perforation of the intestine in IBD. An OMGE survey. Scand J Gastroenterol 23 (Suppl 144): 24–26
Robert JH et al. (1990) Management of severe hemorrhage in ulcerative colitis. Am J Surg 159: 550–555
Jewell DP et al. (1991) Working Team Report. Indications and timing of surgery for severe ulcerative colitis. Gastroenterol Int 4: 161–164
Cohen JL (2005) Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 48: 1997–2009
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Caprilli, R., Viscido, A. & Latella, G. Current management of severe ulcerative colitis. Nat Rev Gastroenterol Hepatol 4, 92–101 (2007). https://doi.org/10.1038/ncpgasthep0687
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0687
This article is cited by
-
Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?
Wiener klinische Wochenschrift (2015)
-
History of and current issues affecting surgery for pediatric ulcerative colitis
Surgery Today (2013)
-
Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements
American Journal of Gastroenterology (2012)
-
Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis
Internal and Emergency Medicine (2012)
-
Acute and chronic megacolon
Current Treatment Options in Gastroenterology (2007)